T0	Participants 124 183	in patients with mixed dyslipidaemia and metabolic syndrome
T1	Participants 376 405	the metabolic syndrome (MetS)
T2	Participants 582 627	in patients with mixed dyslipidaemia and MetS
T3	Participants 651 919	randomised patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day (R group, n = 30) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group, n = 30) or ω-3 fatty acids 2 g/day (Rω group
T4	Participants 937 1045	present study, only patients with MetS were included (24, 23 and 24 in the R, RF and Rω groups respectively)